Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Bristol Myers Squibb sets October 29 results date for Bristol Myers Squibb stock

Dividend Earnings report AI-generated analysis

πŸ“… Bristol Myers Squibb has set October 29, 2026, as the date for its third-quarter earnings results.

πŸ’° The company declared a quarterly dividend of USD 0.63 per share payable on November 2, 2026.

πŸ“ˆ Second-quarter 2026 revenue reached USD 12.97 billion, marking a 6% increase from the prior-year quarter.

πŸ’΅ GAAP diluted earnings per share for the second quarter were USD 1.62 with net earnings of USD 3.32 billion.

πŸš€ The Growth Portfolio generated USD 7.56 billion in quarterly revenue, up 15% year-over-year.

πŸ“‰ The Legacy Portfolio revenue declined by 4% to USD 5.42 billion during the second quarter.

🏦 Analyst Piper Sandler raised its price target from USD 75.00 to USD 82.00 and kept an Overweight rating.

πŸ“Š As of September 30, 2026, the stock had a market capitalization of USD 127.5 billion.

πŸ“‰ The stock traded within a 52-week range of USD 42.52 to USD 68.64 as of late September.

Bullish Signals
  • Bristol Myers Squibb delivered robust second-quarter revenue growth of 6% year-over-year, reaching USD 12.97 billion.
  • The Growth Portfolio demonstrated strong momentum with a 15% increase in quarterly revenue to USD 7.56 billion.
  • Analyst Piper Sandler raised its price target to USD 82.00 and maintained an Overweight rating on the stock.
  • The company reported solid net earnings of USD 3.32 billion for the second quarter of 2026.
Risk Factors
  • Revenue from the Legacy Portfolio declined by 4% year-over-year to USD 5.42 billion in the second quarter.
  • The stock is currently trading 9.09% below its 52-week high of USD 68.64 as of September 30, 2026.
Full Analysis
Bristol Myers Squibb (BMY) has announced that it will report its third-quarter financial results on October 29, 2026. This scheduled release serves as a key market checkpoint following the company's strong second-quarter performance in 2026, where revenue reached USD 12.97 billion, representing a 6% increase year-over-year. During the second quarter of 2026, Bristol Myers Squibb reported GAAP diluted earnings per share of USD 1.62 and net earnings attributable to the company of USD 3.32 billion. The company's Growth Portfolio drove significant expansion with quarterly revenue of USD 7.56 billion, up 15%, while the Legacy Portfolio saw a decline of 4% to USD 5.42 billion. Regarding shareholder returns, Bristol Myers Squibb declared a quarterly dividend of USD 0.63 per share on September 16, 2026, with the payment scheduled for November 2, 2026, for shareholders of record on October 2, 2026. Analyst Piper Sandler recently raised its price target to USD 82.00 and maintained an Overweight rating, citing continued growth in the company's portfolio mix. As of late September 2026, Bristol Myers Squibb had a market capitalization of USD 127.5 billion and was trading within a 52-week range of USD 42.52 to USD 68.64. The upcoming Q3 report will be closely watched to determine if the momentum from the second quarter can be sustained.